No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia (vol 32, pg 87, 2014)

Racil Zdenek; Razga Filip; Klamova Hana; Voglova Jaroslava; Belohlavkova Petra; Malaskova Ludmila; Potesil David; Muzik Jan; Zackova Daniela; Polakova Katerina Machova; Zdrahal Zbynek; Malakova Jana; Suttnar Jiri; Dyr Jan; Mayer Jiri

首页> 外文期刊>Hematological oncology >No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia (vol 32, pg 87, 2014)

【24h】

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia (vol 32, pg 87, 2014)

机译：没有临床证据可对慢性粒细胞性白血病患者进行低谷血浆和细胞内伊马替尼浓度监测（第32卷，第87页，2014年）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hematological oncology》 |2014年第3期|共1页
作者
Racil Zdenek; Razga Filip; Klamova Hana; Voglova Jaroslava; Belohlavkova Petra; Malaskova Ludmila; Potesil David; Muzik Jan; Zackova Daniela; Polakova Katerina Machova; Zdrahal Zbynek; Malakova Jana; Suttnar Jiri; Dyr Jan; Mayer Jiri;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia (vol 32, pg 87, 2014) [J] . Racil Zdenek, Razga Filip, Klamova Hana, Hematological oncology . 2014,第3期

机译：没有临床证据可对慢性粒细胞性白血病患者进行低谷血浆和细胞内伊马替尼浓度监测（第32卷，第87页，2014年）
2. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia [J] . Adeagbo B. A., Bolaji O. O., Olugbade T. A., Journal of Clinical Pharmacy and Therapeutics . 2016,第5期

机译：CYP3A5 * 3和ABCB1 C3435T对尼日利亚慢性粒细胞白血病患者临床结果和伊马替尼谷浓度的影响
3. Imatinib dose escalation for chronic phase|[ndash]|chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400|[thinsp]|mg daily standard therapy [J] . D Rea, G Etienne, S Corm, Leukemia . 2009,第6期

机译：慢性阶段性[| ndash] |慢性粒细胞性白血病患者的伊马替尼剂量递增，对伊马替尼的初次最佳反应为400 | [thinsp] | mg每日标准治疗
4. A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib [O] . Suella Martino, Etienne Daguindau, Christophe Ferrand, 2013

机译：尼洛替尼对伊马替尼耐药的慢性粒细胞性白血病患者在达沙替尼诱导的血栓性血小板减少性紫癜后成功进行肾衰竭肾移植
5. The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study [O] . Van Obbergh, F, Knoops, L, Devos, T, 2017

机译：伊马替尼血浆谷浓度在慢性粒细胞白血病中的临床意义。比利时的研究

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia (vol 32, pg 87, 2014)

著录项

相似文献

相关主题

期刊订阅